IAG, Image Analysis Group
IAG is a London-based imaging CRO whose DYNAMIKA™ platform centralizes image management, central reads, and AI-enabled quantitative analysis for clinical trials. It serves pharmaceutical and biotechnology sponsors across oncology, immunology, neurology, metabolic, and rare disease programs globally.
- Company typePrivate
- Founded2007
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What IAG, Image Analysis Group does
Image Analysis Group (IAG) is a London-headquartered imaging contract research organization (iCRO) founded in 2007 that provides centralized image management, radiological review, and AI-enabled quantitative imaging analysis for clinical trials sponsored by pharmaceutical and biotechnology companies. The company has supported more than 700 trials globally across all phases and therapeutic areas including oncology, neuro-oncology, musculoskeletal and autoimmune diseases, metabolic and obesity indications, and rare diseases. Operating geographies span the UK, continental Europe, North America, India, China, Australia, and Africa, with functional offices in London and Schaumburg (US) and partnership-led operational support across Asia-Pacific.
IAG's core technology is DYNAMIKA™, a proprietary cloud-native clinical trial imaging platform that orchestrates the full imaging pipeline — image acquisition guidance, site uploads, de-identification, real-time quality control, central reads, quantitative analysis, and regulatory-ready data exports — across modalities including MRI, CT, PET, ultrasound, X-ray, and DXA. On top of the platform sit proprietary methodologies such as DEMRIQ (DCE-MRI quantification for synovial inflammation), integrated AI tooling from partners Better Medicine and Picture Health for oncology, and indication-specific scoring systems validated for FDA, EMA, and other regulatory submissions. Platform and processes are aligned to FDA 21 CFR Part 11, ISO 13485, GDPR, HIPAA, and SOC 2 Type II (completed March 2026).
IAG generates revenue through professional-services contracts for imaging CRO engagements — typically multi-year, quote-based, and structured around trial complexity, modality mix, site count, and service scope (startup, site training, central reads, adjudication, exploratory biomarkers, and DYNAMIKA licensing). Customers are predominantly enterprise pharma and biotech (Eli Lilly, Roche, Novo Nordisk, Amgen, Takeda, Ferring) plus academic research consortia, sold via direct enterprise field sales rather than resellers, with thought-leadership content and presence at conferences such as SCOPE Summit, IO360, and HBI driving top-of-funnel demand.
IAG, Image Analysis Group firmographics
Firmographics- Name
- IAG, Image Analysis Group
- Legal name
- Image Analysis Ltd Limited Company
- Website
- https://ia-grp.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- IAG is a London-based imaging CRO whose DYNAMIKA™ platform centralizes image management, central reads, and AI-enabled quantitative analysis for clinical trials. It serves pharmaceutical and biotechnology sponsors across oncology, immunology, neurology, metabolic, and rare disease programs globally.
- Ownership category
- akta.pro rank
IAG, Image Analysis Group industry classification
Industry- Product category
- Imaging Contract Research Services (Clinical Trial Imaging)
- NAICS
- Scientific Research and Development Services (5417), Custom Computer Programming Services (541511), Software Publishers (5132)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL)
Keywords
Where IAG, Image Analysis Group is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices6 records
Markets served
IAG, Image Analysis Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Imaging CRO Services: IAG provides end-to-end imaging contract research services for clinical trials across all phases (Phase I-III) and therapeutic areas. Revenue is generated through service contracts that include imaging charter development, site training, data management, central reads, adjudication, and platform licensing. Pricing is structured around trial complexity, number of sites, imaging modalities, and service scope including optional AI-enabled biomarkers and country expansions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Trial-specific pricing based on scope and complexity |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
IAG, Image Analysis Group product offering
Product offeringCore offering
IAG is a science-driven imaging contract research organization (iCRO) that provides end-to-end centralized imaging services for pharmaceutical and biotech clinical trials across all phases and therapeutic areas. Its proprietary DYNAMIKA™ cloud-native platform orchestrates image acquisition, quality control, central reads, AI-enabled quantitative analysis, and regulatory-ready data exports, complemented by therapeutic-area imaging services in oncology, neuro-oncology, musculoskeletal, liver/metabolic, and rare diseases. Revenue is generated through service contracts (imaging charter development, site training, data management, central reads, adjudication) bundled with platform licensing for sponsors conducting global clinical trials.
Product overview
IAG is a science-driven imaging CRO that operates primarily through its cloud-native DYNAMIKA™ platform, which serves as the central operating system for all clinical trial imaging activities. The platform unifies image acquisition guidance, site uploads, de-identification, quality control, central reads, quantitative analysis, and regulatory-ready data exports. IAG complements the platform with therapeutic area-specific imaging services spanning early and late phase clinical trials, real-world evidence studies, and specialized offerings in oncology, neuro-oncology, musculoskeletal diseases, liver/metabolic diseases, and rare disorders. The DEMRIQ (DCE-MRI Quantification) methodology provides proprietary AI-driven quantitative imaging biomarkers for inflammation assessment. The Collect and Hold solution offers budget-friendly data storage without immediate central review, while AI integrations with Better Medicine and Picture Health extend the platform's automated tumor assessment and imaging biomarker capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- DYNAMIKA™: Proprietary cloud-based clinical trial imaging platform that centralizes image management, quality control, central review, and AI-enabled analytics for clinical trials.
Products and services
- DYNAMIKA™ Clinical Trial Imaging Platform Cloud-native platform that centralizes image acquisition, quality control, anonymization, transfer, central review, and regulatory-ready data exports for clinical trials, with AI-enabled workflows, real-time dashboards, configurable reading forms, and integrated eCRFs for imaging endpoints across all phases and therapeutic areas. Sold to pharmaceutical and biotech sponsors.
- Early Phase Clinical Trial Imaging Imaging support service for Phase I and early Phase II trials focusing on safety, pharmacokinetics, and initial efficacy evidence, including optimal imaging strategy selection, mechanism-of-action assessment, and quantitative endpoint design for oncology, immunology, and rare diseases. Targeted at pharmaceutical and biotech sponsors.
- Late Phase Clinical Trial Imaging Comprehensive imaging support service for Phase III pivotal and global multicenter trials, including real-time QC, digital site training, integrated reader management, sophisticated analytics, and audit-ready data for regulatory submissions. Targeted at pharmaceutical and biotech sponsors running pivotal trials.
- Collect and Hold Imaging Solution Budget-friendly imaging data management service where imaging data is prospectively collected, quality-controlled, and securely stored without immediate central review, with retrospective analysis as required. Targeted at sponsors seeking lower-cost imaging data capture.
- Real-World Evidence and AI Imaging Studies Real-world evidence studies and AI-driven imaging analysis services that complement traditional clinical and claims data with objective visual imaging endpoints. Targeted at pharmaceutical and biotech sponsors seeking AI-enabled biomarker validation.
- Bone Health and Osteoporosis Imaging End-to-end imaging support service for bone health and osteoporosis clinical trials using DXA, QCT, X-ray, and MRI to measure bone mineral density, microarchitecture, and fracture risk with regulatory-grade endpoints. Targeted at sponsors developing osteoporosis and bone fragility therapies.
- Oncology Imaging Comprehensive imaging support service for solid tumor, hematologic malignancy, and sarcoma trials using MRI, CT, PET, and ultrasound with standardized criteria (RECIST, iRECIST, volumetric analysis) and AI-enhanced tumor assessment. Targeted at oncology drug developers.
- Neuro-Oncology Imaging Specialist imaging CRO service for GBM and glioma studies using standardized RANO and RANO 2.0 reads, molecular imaging, and advanced MRI (DWI, DCE-MRI) to distinguish true progression from pseudo-progression. Targeted at sponsors developing brain tumor therapies.
- Musculoskeletal Imaging Imaging service for osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and myositis using X-ray, MRI, DCE-MRI, CT, ultrasound, and DXA with indication-specific scoring systems. Targeted at sponsors developing therapies in inflammatory and autoimmune diseases.
- Liver Disease and MASH/NASH Imaging Standardized MRI protocol service including MRI-PDFF for liver fat quantification and MR elastography for non-invasive fibrosis assessment, supporting patient selection and efficacy endpoints in metabolic liver disease studies. Targeted at sponsors developing MASH/NASH and metabolic liver disease therapies.
Quantifiable outcome
- Protocol deviations related to imaging dropped by 40% in pivotal phase III oncology trial with 80+ global sites
- +4 more outcomes
Companies that use IAG, Image Analysis Group
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles4 records
IAG, Image Analysis Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature5 records
IAG, Image Analysis Group partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and major.
- HeartcoR SolutionscoreStrategic partnership to deliver fully integrated cardiac safety monitoring and imaging core lab services to pharmaceutical and biotechnology sponsors worldwide. Combines HeartcoR's core lab services (ECG, cardiac monitoring, endpoint adjudication) with IAG's multimodality imaging expertise and DYNAMIKA platform. Creates an end-to-end workflow under unified governance to address fragmented vendor relationships and provide coordinated cardiac and imaging data for regulatory submissions.
- Better MedicinecoreStrategic partnership to enhance oncology clinical trial imaging through AI integration. Better Medicine's AI tools are embedded into IAG's DYNAMIKA platform to automate tumor assessment processes, reducing turnaround times and costs while maintaining regulatory standards.
- Picture HealthcoreAI-powered oncology imaging partnership for faster, more precise clinical trials. Integrates Picture Health's AI capabilities with DYNAMIKA platform for tumor response data and imaging biomarker analysis.
- WHO-ESCEO-IOF PRECCOmajorPartnership on osteoporosis and bone health research using advanced imaging. Supports global bone health initiatives and clinical trials for osteoporosis treatments.
- Ferring PharmaceuticalscoreAI-driven imaging collaboration for fertility and women's health using real-world ultrasound data from Fertility Centers of Illinois and Dexeus in Barcelona. The partnership aims to validate predictive AI models for identifying optimal conception timing and create regulator-ready imaging endpoints for fertility clinical trials. This collaboration represents one of the first efforts to translate AI-driven imaging biomarkers from clinical trials into real-world fertility practice.
- Eli Lilly and CompanycoreLong-standing strategic collaboration on AI-powered MRI for IBD clinical trials, with IAG leading imaging strategy and AI-enabled image analysis using DYNAMIKA platform. Partnership has expanded to include obesity and metabolic disease imaging programs.
- Robarts Clinical TrialscoreStrategic collaboration with IAG and Eli Lilly to validate AI-enabled MRI biomarkers for Crohn's disease. Robarts provides clinical expertise and patient-focused insights for endpoint validation in IBD trials.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
IAG, Image Analysis Group competitors and assessment
Company assessmentEmerging players
- Perspectum: Perspectum develops AI-driven quantitative imaging biomarkers, particularly in metabolic and liver disease, and partners with pharma on clinical trials. Comparable to IAG's liver/MASH imaging and AI biomarker work.
- Median Technologies: Median Technologies offers iCRO imaging services and AI-based image analysis for oncology clinical trials. Direct overlap with IAG's oncology imaging and AI-enabled tumor assessment offerings.
- QMENTA: QMENTA provides a cloud imaging platform for clinical trials and research, focused on neurology. It competes with IAG's DYNAMIKA in CNS trial image management and AI biomarker delivery.
Broad incumbents
- Labcorp Drug Development: Labcorp's drug development segment (formerly Covance) operates a large central laboratory and imaging services business. Overlaps with IAG in clinical trial imaging endpoints and central review for pharma sponsors.
- IQVIA: IQVIA is the world's largest CRO with imaging capabilities embedded in its full-service portfolio. Competes for the same large pharma trials as IAG but bundles imaging with broader clinical and commercial services.
- ICON plc: ICON is a top-3 global CRO with established imaging and biomarker services. It is a broad incumbent competitor to IAG, especially on pivotal Phase III programs where sponsors prefer single-vendor outsourcing.
Direct peers
- IXICO: IXICO is a specialist imaging CRO focused on neuroscience and rare disease clinical trials using AI-enabled image analysis. Comparable to IAG's neuro-oncology and quantitative imaging biomarker work, especially in CNS trials.
- Clario: Clario (formed from the merger of BioClinica and ERT) is a dedicated imaging and eCOA CRO serving global clinical trials. It is the most direct competitor to IAG's imaging CRO and DYNAMIKA-style platform offerings across oncology, neurology, and musculoskeletal indications.
- Calyx: Calyx (formerly Parexel Informatics) offers medical imaging management and eClinical solutions for clinical trials. Competes with IAG in central imaging review, regulatory submission support, and platform-based trial enablement.
- Invicro (Medpace): Invicro, now part of Medpace, provides imaging core lab and biomarker services for clinical trials across oncology and CNS. Directly comparable to IAG's full-service imaging CRO model and platform-driven central reads.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
IAG, Image Analysis Group social profiles
Digital presenceIAG, Image Analysis Group compliance and trust
Trust signalCompliance5 records
IAG, Image Analysis Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
IAG, Image Analysis Group leadership team
Management profileNumber of profiles
Profiles6 records
IAG, Image Analysis Group funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IAG, Image Analysis Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IAG, Image Analysis Group
What does IAG, Image Analysis Group do?
IAG is a science-driven imaging contract research organization (iCRO) that provides end-to-end centralized imaging services for pharmaceutical and biotech clinical trials across all phases and therapeutic areas. Its proprietary DYNAMIKA™ cloud-native platform orchestrates image acquisition, quality control, central reads, AI-enabled quantitative analysis, and regulatory-ready data exports, complemented by therapeutic-area imaging services in oncology, neuro-oncology, musculoskeletal, liver/metabolic, and rare diseases. Revenue is generated through service contracts (imaging charter development, site training, data management, central reads, adjudication) bundled with platform licensing for sponsors conducting global clinical trials.
Is IAG, Image Analysis Group a public or private company?
IAG, Image Analysis Group is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was IAG, Image Analysis Group founded?
IAG, Image Analysis Group was founded in 2007. It employs 51 to 100 people.
Where is IAG, Image Analysis Group based?
IAG, Image Analysis Group is headquartered in London, United Kingdom, in the Europe region.
How does IAG, Image Analysis Group make money?
One revenue line is on record: imaging CRO Services.
Who are IAG, Image Analysis Group's main competitors?
Emerging players on record are Perspectum, Median Technologies and QMENTA. Broad incumbents are Labcorp Drug Development, IQVIA and ICON plc. Direct peers are IXICO, Clario, Calyx and Invicro (Medpace).
Does IAG, Image Analysis Group have an API?
No public API is recorded for IAG, Image Analysis Group.
What industry is IAG, Image Analysis Group in?
IAG, Image Analysis Group's product category is Imaging Contract Research Services (Clinical Trial Imaging). Its primary akta.pro industry code is HLAGACAL, Site Data Management Support (EDC/Source/SDV Readiness). Its NAICS code is 5417 and its SIC code is 8731.